Fig. 6
- ID
- ZDB-FIG-250528-6
- Publication
- Chen et al., 2025 - The combination of midkine inhibitor with Lenvatinib amplifies the suppression of hepatocellular carcinoma
- Other Figures
- All Figure Page
- Back to All Figure Page
The combination of iMDK and Lenvatinib inhibits the growth of subcutaneous tumors in a mouse model of HCC. (A) Overview diagram of animal experiments. (B) Physical representation of subcutaneous tumors in mice during sample collection. Tumor volumes were calculated using the formula (length × width2)/2. Compare the significance of the difference between each group and the blank group using Student's t-test. (C) Body weight changes in mice throughout the administration period, with day 0 marked as the day of administration. (D) Results of H&E staining and IHC with HCC. Quantification of positive areas with ImageJ 2 software. Probability values p < .05 denote statistical differences, with statistical significance marked by “*” for p < .05 and “**” for p < .01. Six individuals were included in each experimental group (n = 6). All these experiments were conducted three times in a double-blind manner, and the quantification results are presented as the mean ± SD. |